Candel Therapeutics (CADL) announced the appointment of Elizabeth Jaffee, M.D., to the Company’s Research Advisory Board, RAB. Dr. Jaffee brings her extensive expertise to the RAB, which is important in light of the Company’s focus on borderline resectable pancreatic cancer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Reports Positive Clinical Trial Results
- Promising Clinical Results and Strong Potential of Candel Therapeutics’ CAN-2409 Justify Buy Rating
- Candel Therapeutics: Promising Clinical Developments and Strong Buy Rating
- Candel Therapeutics reports Q4 EPS (40c), consensus (23c)
- Candel Therapeutics price target raised to $25 from $20 at Canaccord